For the purpose of eradication programmes for infection with rabies virus (RABV), anti-rabies vaccination must only be carried out on pet animals that are identified and must fulfil the requirements laid down in Annex III to Regulation (EU) No 576/2013 of the European Parliament and of the Council [Regulation (EU) No 576/2013 of the European Parliament and of the Council of 12 June 2013 on the non-commercial movement of pet animals and repealing Regulation (EC) N0 998/2003 (OJ L 178, 28.6.2013, p. 1).].
For the purpose of eradication programmes for infection with RABV, anti-rabies vaccination of kept animals, other than those referred to in the first paragraph, must be risk-based and carried out with the purpose of protecting humans from being exposed to rabies virus, using vaccines that meet the requirements laid down in points (1)(a) and (1)(b)of Annex III to Regulation (EU) No 576/2013 of the European Parliament and of the Council.
For the purpose of eradication programmes for infection with RABV the oral vaccination against infection with RABV of wildlife must:
be organised and implemented as regular planned or emergency campaigns taking into account the risk assessment provided in point (a) of Article 32(2);
be subjected to an adequate vaccine distribution in terms of timing and coverage of the vaccination area, taking into account the biology of the targeted animal population, the epidemiological situation and the topography of the area;
be subjected, with the support of geographical information systems, to assessment of the correct geographical distribution of vaccine baits with a frequency that allows, if necessary, the adoption of corrective measures; and
be subjected to monitoring of vaccination effectiveness, that may include the detection of the presence of biomarker and serological testing in dead animals from the targeted animal population for the vaccination.
For the purpose of eradication programmes for infection with RABV the vaccination against infection with RABV of stray dog populations must:
be organised and implemented, if necessary, as part of control and management measures of stray dog populations, taking into account the risk assessment provided for in point (a) of Article 32(2);
comply with the requirements of Section 1.
The status free from infection with RABV may only be granted to a Member State or a zone if:
surveillance has been implemented in accordance with the requirements laid down in Article 3(1) at least for the past 24 months; and
no case of infection with RABV has been confirmed during the past 24 months in the targeted animal population.
By way of derogation from point 1(b), if a case of infection with RABV has been confirmed, the status may be granted if the infection of the case did not occur in the Member State or in the zone; and
the case has been officially confirmed and no epidemiological link may have occurred and resulted in any additional case, which includes detection of the case at a border control post, or in a quarantine establishment or the quarantine facilities of a confined establishment; or
epidemiological link may have occurred and no additional case was detected by increased surveillance and epidemiological enquiry and investigations during the 6 months following the death of the case.
The status free from infection with RABV of a Member State or a zone may only be maintained if:
surveillance is implemented in accordance with the requirements laid down in Article 3(1) with the objective of an early detection of the disease; and
no case of infection with RABV has been confirmed in the targeted animal population or a case occurred and the conditions laid down in point 2 of Section 1 were complied with.
The surveillance of infection with bluetongue virus (serotypes 1-24) (infection with BTV) to ensure early detection of introduction or recurrence of infection with any of the serotypes 1-24 of BTV that were not reported during the previous 2 years must include:
general surveillance requirements as provided for in point (a) of Article 3(1);
active surveillance as provided for in Section 4.
The design of the surveillance provided for in point 1 must address:
the risk of infection with limited clinical manifestations;
the risk of introduction of BTV serotypes associated with the circulation of any of the serotypes 1-24 of BTV in the vicinity; and
any other identified relevant risk factor for introduction of any of the serotypes 1-24 of BTV not reported in the previous 2 years.
The surveillance in an area(s) adjacent to any infected Member State, zone or third country must be increased in an area of up to 150 km from the limit with the Member State, zone, or third country. The demarcation of the area of increased surveillance may be adapted to relevant ecological or geographical features likely to facilitate or interrupt the transmission of BTV or adapted due to the implementation of disease control measures that supports the choice between a greater or lesser distance.
The surveillance provided for in point 1(b) and point 3 must have the capacity at least to detect, with a 95 % level of confidence, the infection in the targeted animal population at a target prevalence rate of 5 %, unless otherwise specified in Section 2 of Chapter 4.
The surveillance of infection with BTV to ensure the timely demarcation of the spread of the infection when one or more serotypes of BTV is present and, if necessary, to monitor the prevalence rate must include:
general surveillance requirements as provided for in point (a) of Article 3(1); and
active surveillance as provided for in Section 4.
The design of the surveillance provided for in point 1 must take into account: all available information on the epidemiology of the disease and biology of the vector that prevail on the territory.
The target prevalence rate of the surveillance provided for in point 1 must be adapted to the epidemiological situation, taking into the main risk factors such as the targeted animal population and the vector population.
The surveillance of infection with BTV to demonstrate the absence of infection with any of the serotypes 1-24 that has been previously detected in the territory must include:
general surveillance requirements as provided for in point (a) of Article 3(1); and
active surveillance as provided for in Section 4.
The design of the surveillance provided for in point 1 must address:
the risk of infection with limited clinical manifestations;
all available information on the epidemiology of the disease and biology of the vector that prevail on the territory; and
any specific risk of persistence of the infection identified.
The surveillance provided for in point 1(b) must have the capacity at least to detect, with a 95 % level of confidence, the infection in the targeted animal population at a target prevalence rate of 1 %.
The geographical units referred to in point (a) of Article 40(1) must be based on a grid of 45 km by 45 km and can be adapted to:
the epidemiological situation, how fast the infection is spreading and the shape and size of the zones covered by the eradication programme in the event of confirmation of the infection; and
the zones in accordance with point (b) of Article 13(2).
Active surveillance must be based on one or a combination of the following activities:
monitoring of sentinel animals using serological or virological testing; and
structured prevalence surveys, based on a random or risk-based sampling strategy using serological or virological testing.
The frequency of the sampling must:
at least be annual, in the period of the year when infection or seroconversion is most likely to be detected; and
be monthly during the vector activity season where regular information is needed due to the risk of the infection spreading.
The animals sampled must:
not be vaccinated against the serotype(s) of BTV targeted for surveillance;
no longer be covered by maternal immunity in case their mother was vaccinated or infected;
be resident for a sufficient time in the relevant geographical unit and not have been protected from exposure to the vector;
be representative for the geographical distribution of the targeted animal population in the relevant geographical unit; and
be initially seronegative when surveillance is based on serological testing of sentinels.
The sample size in each geographical unit must be calculated in accordance with the target prevalence rate based on the objectives assigned in Sections 1-3.
When surveillance must be adapted as provided for in point (c) of Article 43(2), it must at least include a survey:
on the introduced animals that:
must be based on the sampling and testing of all introduced animals;
must take place as soon as possible after their introduction; or
on the targeted animal population the most at risk due to the possible circulation of the virus that:
must have a capacity at least to detect, with a 95 % level of confidence, infection with BTV at a target prevalence rate of 5 %;
must either:
not take place before 21 days has elapsed after the introduction of animals if it is a one-shot survey; or
must be conducted with a frequency adapted to the frequency of the movements of the animals that may jeopardise the health status.
This survey is not required if the frequency of the sampling is carried out in accordance with point 3(b).
Entomological surveillance must consist of at least an active annual programme of vector catching by means of permanently sited aspiration traps intended to determine the population dynamics of the vector and, where relevant, the vector-free period.
Aspiration traps equipped with ultraviolet light must be used in accordance with pre-established protocols; the traps must be operated throughout the night and operate at least:
one night per week during the month before the expected beginning and during the month before the expected end of the vector-free period; and
one night per month during the vector-free period.
On the basis of the evidence obtained in the first 3 years of operating the aspiration traps, the frequency of operation of those traps may be adjusted.
At least one aspiration trap must be placed in each geographical unit referred to in point (a) of Article 40(1) throughout the seasonally BTV-free zone. A proportion of the midges collected in the aspiration traps must be sent to a specialised laboratory capable of counting and identifying the suspected vector species or complexes.
When entomological surveillance is organised in the context of determination of a vector-free period, a maximum threshold of Culicoides species must be defined for the interpretation of the results. In the absence of sound evidence supporting the determination of the maximum threshold, total absence of Culicoides imicola specimens and less than five parous Culicoides per trap must be used as maximum threshold.
The animals originate from a Member State or a zone free from infection with BTV and have not been vaccinated with a live vaccine against infection with BTV in the last 60 days before the date of movement.
The animals originate from a Member State or a zone covered by the eradication programme and at least one of the following requirements is complied with:
the animals have been kept in a seasonally BTV-free Member State or zone established in accordance with paragraph 3 of Article 40:
for at least 60 days prior to the date of movement;
for at least 28 days prior to the date of movement and have been subjected to a serological test, with negative results, carried out on samples collected at least 28 days following the entry date of the animal into the seasonally BTV-free Member State or zone; or
for at least 14 days prior to the date of movement and have been subjected to a PCR test, with negative results, carried out on samples collected at least 14 days following the entry date of the animal into the seasonally BTV-free Member State or zone;
the animals have been protected against attacks by the vectors during transportation to the place of destination and they have been kept protected against attacks by vectors in a vector protected establishment:
for at least 60 days prior to the date of movement; or
for at least 28 days prior to the date of movement and have been subjected to a serological test, with negative results, carried out on samples collected at least 28 days following the date of the commencement of the period of protection against attacks by vectors; or
for at least 14 days prior to the date of movement and have been subjected to a PCR test, with negative results, carried out on samples collected at least 14 days following the date of commencement of the period of protection against attacks by vectors;
the animals have been vaccinated against all serotypes 1-24 of BTV reported during the past 2 years in that Member State or zone, the animals are within the immunity period guaranteed in the specifications of the vaccine and meet at least one of the following requirements:
they have been vaccinated more than 60 days before the date of movement; or
they have been vaccinated with an inactivated vaccine and subjected to a PCR test, with negative results on samples collected at least 14 days after the onset of the immunity set in the specifications of the vaccine.
the animals have been subjected with positive results to a serological test able to detect specific antibodies against all serotypes 1-24 of BTV reported during the past 2 years in that Member State or zone and:
the serological test have been carried out on samples collected at least 60 days before the date of movement; or
the serological test have been carried out on samples collected at least 30 days before the date of the movement and the animals have been subjected to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of movement.
The animals originate from a Member State or a zone neither BTV-free nor covered by an eradication programme for infection with BTV and:
they comply with point 2(b); or
the animals have been kept at least for the last 60 days prior to departure either in an area of at least 150 km radius from the establishment where they are kept, or in a Member State, where surveillance in compliance with the requirements laid down in Sections 1 and 2 of Chapter 1 have been carried out at least for the last 60 days prior to departure and:
they have been vaccinated in accordance with point 2(c) against all serotypes 1-24 of BTV reported during the past 2 years in an area of at least 150 km radius centred on the place where the animals were kept; or
they have been immunised in accordance with point 2(d) against all serotypes 1-24 of BTV reported during the past 2 years in an area of at least 150 km radius centred on the place where the animals were kept.
The animals originate from a Member State or a zone not BTV-free, are destined for immediate slaughter and the following requirements apply:
no case of infection with BTV has been reported in the establishment of origin for a period of at least 30 days prior to the date of movement;
the animals are transported directly from the Member State or zone of origin to the slaughterhouse of destination where they are slaughtered within 24 hours of arrival;
the operator of the establishment of origin have informed the operator of the slaughterhouse of destination of the movement at least 48 hours prior to the loading of the animals.
The animals originate from a Member State or a zone neither BTV-free nor covered by an eradication programme for infection with BTV and the animals comply with the requirements set out in point 2(a).
The animals originate from a Member State or a zone not BTV-free and:
they have been protected from vector attacks by insecticides or repellents for at least 14 days prior to the date of movement; and
they have been subjected during that period to a PCR test, with negative results, carried out on samples collected at least 14 days following the date of protection from vector attacks.
The animals comply with specific animal health requirements defined by the competent authority to ensure they have sufficient immunological protection prior to departure.
The animals comply with any of the requirements provided for in points 2, 3 5, 6 or 7 only for the serotypes of BTV reported for the past 2 years in the Member State or zone of origin and not in the Member State or zone of destination during the same period.
The donor animals have been kept at least for a period of 60 days prior to and during the collection of germinal products in a Member State or a zone free from infection with BTV.
The germinal products originate from a Member State or a zone covered by the eradication programme for infection with BTV and at least one of the requirements set out in point (a) for semen, point (b) for in vivo derived embryos of bovine animals or point (c) for embryos other than in vivo derived embryos of bovine animals and oocytes is complied with:
semen have been obtained from donor animals that comply with at least one of the following requirements:
they have been protected against attacks by vectors in a vector protected establishment for a period of at least 60 days before commencement of collection and during collection of the semen;
they have been kept in a seasonally BTV-free Member State or zone for a period of at least 60 days before commencement of collection and during collection of the semen;
they have been subjected to a serological test, with negative results, on samples collected between 28 and 60 days from the date of each collection of the semen;
they have been subjected, with negative results, to a direct diagnostic method carried out on samples collected:
at commencement and final collection of the semen to be consigned; and
during the period of semen collection: at least every 7 days in the case of a virus isolation test, or at least every 28 days, in the case of a PCR test;
in vivo derived embryos of bovine animals have been obtained from donor animals that do not show any clinical signs of infection with BTV on the day of collection and are collected, processed and stored in accordance with Part 2 of Annex III of Commission Delegated Regulation (EU) 2020/686 [Commission Delegated Regulation (EU) 2020/686 of 17 December 2019, supplementing Regulation (EU) 2016/429 of the European Parliament and of the Council as regards the approval of germinal product establishments and the traceability and animal health requirements for movements within the Union of germinal products of certain kept terrestrial animals (see page 1 of this Official Journal).];
embryos other than in vivo derived embryos of bovine animals and oocytes have been obtained from donor animals that comply with at least one of the following requirements:
they have been protected against attacks by vectors in a vector protected establishment for at least 60 days before commencement of collection and during collection of the embryos/oocytes;
they have been subjected to a serological test, with negative results, on samples collected between 28 and 60 days from the date of each collection of the embryos/oocytes;
they have been subjected to a PCR test, with negative results, on samples collected on the day of collection of the embryos/oocytes;
they have been kept in a seasonally BTV-free Member State or zone for a period of at least 60 days before collection of the embryos/oocytes.
The germinal products originate from a Member State or a zone neither BTV-free nor covered by an eradication programme for infection with BTV and comply with the requirements set out either in point 2(a)(i), 2(a)(iii), 2(a)(iv), 2(b), 2(c)(i), 2(c)(ii) or 2(c)(iii).
The germinal products originate from a Member State or a zone neither BTV-free nor covered by an eradication programme for infection with BTV and must comply with either point 2(a)(ii) or 2(c)(iv).
The status of vector protected establishment may only be granted to an establishment if:
it has appropriate physical barriers at entry and exit points;
openings must be vector screened with mesh of appropriate gauge which must be impregnated regularly with an approved insecticide according to the manufacturers’ instructions;
vector surveillance and control must be carried out within and around the vector protected establishment;
measures must be taken to limit or eliminate breeding sites for vectors in the vicinity of the vector protected establishment; and
standard operating procedures must be in place, including descriptions of back-up and alarm systems, for operation of the vector protected establishment and transport of animals to the place of loading.
The status free from infection with BTV may only be granted to a Member State or to a zone, where BTV has never been reported, if:
surveillance in accordance with Section 1 of Chapter 1 has been conducted at least for the past 24 months; and
no case of infection with BTV has been confirmed during the past 24 months in the targeted animal population.
The status free from infection with BTV may only be granted to a Member State or to a zone where BTV has already been reported if:
surveillance in accordance with Section 3 of Chapter 1 has been conducted at least for the past 24 months; and
no case of infection with BTV has been confirmed during the past 24 months in the targeted animal population.
The status free from infection with BTV may only be maintained if:
the requirements laid down in point 1 of Section 1 are complied with; and
animals and germinal products from the targeted animal population are only moved into or through the Member State or zone when the requirements laid down in Articles 43 and 45 are complied with.
The intensity and frequency of the surveillance referred to in point 1 of Section 1 must be duly adapted to:
the health status of neighbouring Member States, zones or third countries in accordance with point 3 of Section 4 of Chapter 1;
the introduction of animals from the targeted animal population that may have jeopardised the health status of the Member State or zone, in accordance with point 6 of Section 4 of Chapter 1.